読み込み中
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
前日終値
$4.42
+$0.19 · +4.49%
日中の時刻はETです。市場データは遅延する場合があります。
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
日中レンジ
現在 $4.42
52週レンジ
現在 $4.42
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
21
割高
センチメント
43
まちまち
リスク
80
高リスク
モメンタム
26
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
日中レンジ
現在 $4.42
52週レンジ
現在 $4.42
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | 9.3万 USD | 12万 USD | — | — |
| 売上原価 | — | 5万 USD | 7.7万 USD | 45.2万 USD | — |
| 粗利益 | — | 4.3万 USD | 4.3万 USD | −45.2万 USD | — |
| 研究開発 | 7453.6万 USD | 7047.1万 USD | 3803.8万 USD | 3435.4万 USD | 2643.5万 USD |
| 販売・一般管理 | 2228万 USD | — | — | 1457.9万 USD | 1049.3万 USD |
| 営業費用 | 9681.6万 USD | 9357.4万 USD | 5087.9万 USD | 4893.3万 USD | 3692.8万 USD |
| 受取利息 | 154万 USD | 414.6万 USD | 126万 USD | 79.7万 USD | — |
| 支払利息 | — | — | — | — | 144.2万 USD |
| 減価償却費と償却費 | 112.9万 USD | 67.7万 USD | 28.6万 USD | 45.2万 USD | 67.6万 USD |
| 営業利益 | −9681.6万 USD | −9353.1万 USD | −5083.6万 USD | −4938.5万 USD | −3692.8万 USD |
| 純利益 | −1.41億 USD | −6869.4万 USD | −7709.1万 USD | −4645.3万 USD | −3873.5万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
評価サンプルは3件と限定的です
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
